BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
These three stocks have received a rare double upgrade from analysts since their most recent earnings reports; fortunately investors still have time to catch up
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.
CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda.
